Lutetium Lu 177 Dotatate

**Semantic type:** Amino Acid, Peptide, or Protein|Pharmacologic Substance

**Definition:** A radioconjugate consisting of the tyrosine-containing somatostatin analog Tyr3-octreotate (TATE) conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope lutetium Lu 177, with potential imaging and antineoplastic activities. Lutetium Lu 177 dotatate binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. Tyr3-octreotate (TATE) is an octreotide derivative in which phenylalanine at position 3 is substituted by tyrosine and position 8 threoninol is replaced with threonine. SSTRs have been shown to be present in large numbers on NET and their metastases, while most other normal tissues express low levels of SSTRs.

**Synonyms:** - 177 Lu-DOTA-TATE - 177 Lu-DOTA-Tyr3-Octreotate - 177Lu-DOTA0-Tyr3-Octreotate - LUTETIUM OXODOTREOTIDE LU-177 - Lutathera - Lutetium (177Lu) Oxodotreotide - Lutetium Lu 177 DOTA(0)-Tyr(3)-Octreotate - Lutetium Lu 177 dotatate - Lutetium Lu 177-DOTA-Tyr3-Octreotate - Lutetium Oxodotreotide Lu-177 - lutetium Lu 177-DOTATATE